Слайд 1 Astana Medical University
Department of Internal Disease №1
SIW
Topic: chronic lymphocytic
leucosis
Made by Yeleukenova Zhanel 463 GM
Check by Baidurin S.
A.
Astana 2018
Слайд 2Сhronic lymphocytic leucosis
The chronic lymphocytic leucosis is a widespread kind
of a blood cancer at which emergence of the pathological
mature neoplastic lymphocytes having abnormally long life expectancy is observed.
Слайд 3Etiology
More than 2/3 all patients passed an age threshold in
60 years.
Слайд 5Pathogenesis
There is a mutation of cells of predecessors of lymphocytes,
DNA is programmed on a proliferation of abnormal lymphocytes.
At first
the damaged lymphocytes gather in lymph nodes. After achievement of a certain quantity they with current of a lymph migrate in a lien and a liver, thus, promoting augmentation of the sizes of the above-named organs. In process of the attack of marrow, malignant lymphocytes replace normal cells, provoking, anemic processes and reduction of quantity of healthy formulated elements of a blood. In parallel to these processes note decrease of the activity of antibodies.
Слайд 6Clinics
Often at early stages the chronic lymphocytic leukosis doesn't prove
in any way. If symptoms nevertheless appeared, belong to them:
The
lymphadenitis which isn't followed by pain
Fatigue
Temperature increase
Pain in the top left part of a stomach which can be caused by lien augmentation
Night sweating
Loss of weight
Frequent infections
Слайд 8The generalized lymphadenitis which merge in huge soft or dense
packages becomes perceptible.
The lien reaches the appreciable sizes, its mass
is enlarged
Слайд 10Group A (forecast good, more than 10-year survival) HB> 100
g/l; the quantity of thrombocytes > 100x10/l is struck less
than 3 organs
Group B (the forecast intermediate) the Maintenance of HB and thrombocytes the same, as in group A; 3 organs and more are struck
Group C (forecast bad, less than 2-year survival) HB <100 g/l; quantity of thrombocytes <100x10/l
Слайд 11Diagnosis
Blood test. By quantity of blood cells and their look
under a microscope it is possible to suspect a leucosis.
Most of patients with a chronic leucosis has an increased quantity of leucocytes and l, depression of number of erythrocytes and lymphocytes d thrombocytes. The maintenance of cells of a leykolizis is enlarged (Botkin's – Gumprekht cells)
Biochemical blood test helps to specify function of kidneys and structure of a blood.
The research of marrow gives the chance to establish the diagnosis of a leukosis and to estimate efficiency of treatment. Hyperplasia of lymphocytic elements.
Слайд 12For the purpose of specification like a leukosis special methods
of a research are used: cytochemistry, flowing cytometry, immunocytochemistry, cytogenetics
and molecular and genetic research.
X-ray inspections of a thorax and bones allow to tap a lesion of lymph nodes of a mediastinum, bones and joints.
The Computer Tomography (CT) gives the chance to find a lesion of lymph nodes in a thoracal cavity and a stomach.
Слайд 13
The Magnetic Resonance Imaging (MRI) is especially shown at a
research of a head and spinal cord.
Ultrasonography (US) allows to
distinguish tumoral and cystic educations, to tap a lesion of kidneys, liver and lien, lymph nodes.
Слайд 14Treatment
Patients are younger than 70 years and without serious associated
diseases of Hemoimmunoterapiya;
Fludarabin + Cyclophosphamide + Rituximab (FCR);
Fludarabin + Rituximab
(FR);
Pentostatin + Cyclophosphamide + Rituximab (PCR);
Bendamustin + Rituximab (BR);
Obinutuzumab + Hlorambutsil.
Слайд 15Patients are more senior than 70 years, or with serious
associated diseases Obinutuzumab + Hlorambutsil;
Rituximab + Hlorambutsil;
Bendamustin (70 mg/sq.m in
1 cycle with rising to 90 mg/sq.m) + Rituximab (BR);
Cyclophosphamide + Prednizolon± Rituximab;
Rituximab;
Флударабин±Ритуксимаб;
Kladribin;
Hlorambutsil.
Слайд 16Treatment of a recurrence and refractory options of HLL
Choice drug
at treatment of a recurrence and refractory options of HLL
is Ibrutinib. Ibrutinib in a dose of 420 mg is applied (3 x 140-mg in capsules).
Indications for treatment ibrutiniby:
· ECOG status 0-1.
· The diagnosis of HLL, is established according to criteria of the mezhunanarodny working group on studying of HLL, 2008;
· Existence of indications by the beginning of therapy.
· To the patient должнен to be conducted at least one course of therapy of HLL with including of purine analogs or is taped
Слайд 17Complications
Frequent infectious diseases. The people suffering from a chronic lymphocytic
leukosis often have infectious diseases. In most cases it is
infections of the top and lower respiratory tracts. In certain cases there can be more serious infectious diseases.
Formation of more aggressive form of cancer. A small amount of the people suffering from a chronic lymphocytic leukosis can have more aggressive form of cancer, a so-called diffuse V-macrocellular lymphoma. Sometimes such degeneration is called Richter's syndrome.
Слайд 18Augmentation of risk of emergence of other forms of malignant
neoplasms. At the people suffering from a chronic lymphocytic leukosis
the risk of formation of other types of cancer, such as melanoma, cancer of a lung and cancer of digestive tract is increased.
Disturbances from immune system. At a small share of patients with a chronic lymphocytic leukosis the autoimmune disease at which the cells of immune system designed to protect an organism from an infection by mistake attack erythrocytes or thrombocytes develops.